Control of Oral Anticoagulation in Patients with the Antiphospholipid Syndrome – Influence of the Lupus Anticoagulant on International Normalized Ratio

Summary

The recommended therapeutic range of International Normalized Ratio (INR) for oral anticoagulant treatment in patients with the antiphospholipid syndrome remains controversial. As a part of this controversy, it has been suggested that lupus anticoagulants (LA) could interfere with the determination of prothrombin time, thus questioning the validity of monitoring the treatment of these patients using INR. To clarify this point, we compared the values of INR obtained in the plasmas of two groups of patients, one without LA (n = 47), and the other with LA (n = 43). INR were determined using 8 different thromboplastin reagents on the same automated coagulation instrument. Chromogenic factor X, which is supposed to be insensitive to the presence of LA, was also measured. The results are the following: provided INR was calculated using calibrated reference plasmas, there was no significant difference between INR values obtained with the 8 reagents, both in the non-LA and in the LA groups (CV: 5.9 and 6.7%, respectively). Closer examination revealed that INR results obtained with one reagent (the recombinant thromboplastin Innovin) diverged from those of the 7 others, leading to an overestimation of INR, to a very large extent in some instances. However this effect was restricted to a subset of the patient population with LA (6 out of 43). Finally, the relationship between INR (average value obtained using the 8 reagents) and factor X was identical in non-LA and in LA patient groups. We conclude that, provided the reagents which display the LA interference are identified and excluded for this purpose, the INR system is valid for monitoring oral anticoagulant treatment in patients with LA.

• References

• 1 Derksen RHWM, de Groot PG, Kater L. et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-92.
• 2 Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Int Med 1992; 117: 303-8.
• 3 Khamashta MA, Cuadrado MJ, Mujie F. et al. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995; 332: 993-7.
• 4 Palareti G, Coccheri S, Poggi M, Bonetti M, Cervi V, Mazzucca A, Savoia M, Veri L, Fiori F, Gaspari G, Palareti A. Oral anticoagulant control exercise. Thromb Haemost 1987; 58: 905-10.
• 5 Della Valle P, Crippa L, Safa O, Tomassini L, Pattarini E, Vigano D’Angelo S, Sabbanini MG, D’Angelo A. Potential failure of the international normalized ratio (INR) system in the monitoring of oral anticoagulation in patients with lupus anticoagulants. Ann Med Intern 1996; 147: 10-4.
• 6 Moll S, Ortel TL. Monitoring Warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177-85.
• 7 Lawrie AS, Purdy G, Mackie IJ, Machin SJ. Monitoring oral anticoagulation therapy in lupus anticoagulant positive patients with the anti-phospholipid syndrome. Br J Haematol 1997; 98: 887-92.
• 8 Finazzi G, Barbui T. for the International Steening Committee of the WAPS Study. Proposal of clinical trial of high dose warfarin in the anti-phospholipid syndrome: the WAPS Study. Lupus 1996; 5: 556.
• 9 Working Group on Haemostasis of the Société Française de Biologie Clinique. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Thromb Haemost 1993; 70: 781-6.
• 10 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
• 11 Hubbard AR, Margetts SML, Barrowcliffe TW. International normalized ratio determination using calibrated reference plasmas. Br J Haematol 1997; 98: 74-8.
• 12 Bland JM, Altman DG. Comparing methods of measurement: why plotting difference against standard method is misleading. Lancet 1995; 346: 1085-7.
• 13 The Le D, Weibert RT, Sevilla BK, Donnely KJ, Rapaport SI. The International Normalized ratio (INR) for monitoring warfarin therapy: relability and relation to other monitoring methods. Ann Intern Med 1994; 120: 552-8.
• 14 Tripodi A, Arbini A, Chantarangkul V, Mannucci PM. Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test. Thromb Haemost 1992; 67: 42-5.